Physician profile
Jane Mattei
NPI 1821564915
$4,154.99
in general payments reported to CMS, 2019-2025
8 companies · $3,493 in 2025
The $3,493 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $471 · 2024: $191 · 2025: $3,493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $2,000 · Food and Beverage: $1,123 · Travel and Lodging: $755 · Education: $277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $2,000.00 |
| Food and Beverage | $1,123.47 |
| Travel and Lodging | $754.55 |
| Education | $276.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Immunocore Limited | $3,043.05 | 2025 | Kimmtrak |
| Astellas Pharma US INC | $344.67 | 2023-2025 | Padcev |
| Pfizer INC. | $220.16 | 2024-2025 | |
| Caris Mpi, INC. | $171.05 | 2025 | Mi Cancer Seek |
| Emd Serono, INC. | $117.41 | 2023 | Bavencio |
| Array Biopharma INC | $114.21 | 2023-2025 | Braftovi, Mektovi |
| Seagen INC. | $92.99 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $51.45 | 2025 | Libtayo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Mattei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.